Cogent Biosciences shares are trading lower. The company announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis.
Portfolio Pulse from Benzinga Newsdesk
Cogent Biosciences shares are trading lower following the announcement of additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis.
June 14, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cogent Biosciences shares are trading lower after the company released additional data from Part 1 of its SUMMIT clinical trial for bezuclastinib in nonadvanced systemic mastocytosis.
The release of additional data from the clinical trial appears to have been received negatively by the market, leading to a decline in share price. This suggests that the data may not have met investor expectations or raised concerns about the drug's efficacy or safety.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100